43 results about "Conotoxin" patented technology

The invention relates to a skin care composition for improving female climacteric aging and application thereof, and the skin care composition for improving female climacteric aging comprises the following components: conotoxin peptide, bakuchiol, alfalfa extract and radix pseudostellariae extract, the weight ratio of the conotoxin peptide to the bakuchiol to the alfalfa extract to the radix pseudostellariae extract is (0.1-5): (0.1-3): (0.1-5): (0.1-3). By means of inhibiting neurotransmitters, regulating hormones and the like, skin health is enhanced, the problem of skin aging of menopause women is effectively solved, and the skin is tight and smooth.

The invention discloses a mu-type conotoxin peptide mutant as well as a pharmaceutical composition and application thereof. The amino acid sequence of the mu-type conotoxin peptide mutant is as shown in SEQ ID NO. 1. Compared with a wild type mu-type conotoxin peptide, the mu-type conotoxin peptide [d-Arg2, Ser17]-dR-mu-CnIIIC disclosed by the invention has higher activity, the animal activity is improved by more than 20 times, and muscle contraction can be effectively reduced by specifically blocking a Nav1.4 channel. In addition, the compound can be used as a non-invasive anti-wrinkle treatment means to reduce or eliminate the formation of wrinkles on the human skin surface, and has a wide application prospect in the fields of medical treatment and beauty.

The application relates to the cosmetic technical field, and particularly discloses an anti-aging composition for reducing stress fatigue, a preparation method and application thereof. The anti-aging composition comprises a camellia chrysantha extract, a prosopis juliflora seed extract, a mu-conotoxin and an ascorbic acid polypeptide; the mass ratio of the camellia chrysantha extract, the prosopis juliflora seed extract, the mu-conotoxin and the ascorbic acid polypeptide is (0.1-5):(0.01-2):(0.001-1):(0.01-5). The anti-aging composition provided by the application can reduce stress damage of skin cells, improve cell vitality, thereby improving the problems of skin dullness, roughness, looseness and fine lines caused by overwork, work and emotional stress, and is mild and non-irritating, and is suitable for sensitive skin people.

The present invention discloses a Pro.ALP conotoxin peptide for immediate anti-wrinkle and fine line reduction, and the amino acid sequence of the conotoxin peptide is shown as any one of SEQ ID No.1-3. It also discloses its encoding gene, expression vector, host bacterium, biosynthesis method and applications. The present invention uses a prokaryotic system for expression, with a simple system, high yield and low cost. The conotoxin peptides disclosed in the present invention can all be highly expressed in the prokaryotic system, solving the drawbacks of chemical synthesis and reducing the purification difficulty; the biosynthesized conotoxin peptides have the efficacy of stable quality, immediate skin tightening and good solubility, and have good applications in the cosmetic field.

The utility model relates to the technical field of ultrafiltration equipment, in particular to anti-aging and anti-wrinkle ultrafiltration equipment for concentration preparation of conotoxin. The technical problems that a hollow fiber membrane filament structure is mostly adopted in the ultrafiltration process of existing conotoxin, due to the fact that vibration of membrane filaments in the ultrafiltration process may be too large, the membrane filaments are prone to being broken in the operation process, leakage and pollution of conotoxin may be caused, and normal operation of equipment is affected are solved. According to the technical scheme, the anti-aging and wrinkle-removing ultrafiltration equipment for conotoxin concentration preparation comprises an ultrafiltration box, a rectangular sealing cover and a water supply box, after an ultrafiltration membrane is turned over, a connecting water pipe is taken out and is in positioning and clamping connection with the ultrafiltration box along an arc-shaped clamping groove, and meanwhile, a second inserting column drives the connecting water pipe to be fixedly connected with a water outlet pipe through a second inserting hole; then a water source is poured into the water supply tank through the water inlet pipe, enters the water outlet pipe to reach the connecting water pipe through driving of the water pump, and flushes the ultrafiltration membrane through the spray head.

The invention discloses a mu-type conotoxin peptide, polynucleotide encoded by the mu-type conotoxin peptide and application of the mu-type conotoxin peptide. The amino acid sequence of the mu-type conotoxin peptide is shown as SEQ ID NO. 1. The invention provides a mu-type conotoxin peptide with higher biological activity than wild-type mu-type conotoxin, which can specifically block a Nav1.4 channel and reduce muscle contraction so as to be helpful for preventing and reducing wrinkles, and also can provide local anesthesia and reduce muscle activity, thereby playing an important role in the fields of beauty and medical treatment.

The invention belongs to the technical field of biological medicines, and relates to a mutants of mu-conotoxin KIIIA rich in positive charges and application of the mutants. The mutant is obtained by implementing site-specific mutagenesis at the following positions on a mutant as shown in SEQ ID NO.1 in a sequence table: S6R; the amino acid sequence of the mutant is as shown in SEQ ID NO. 2 in a sequence table. According to the invention, systematic structural optimization is carried out on a parent peptide KIIIA containing three pairs of disulfide bonds, and a strategy of combining disulfide bond deletion and amino acid site-directed mutagenesis is adopted, so that a mutant which is simple and convenient to synthesize and has a remarkable inhibition effect on a NaV1.4 channel is obtained. The mutant has high activity, high stability and better pharmacokinetic characteristics, and has wide development potential.

Provided are a μ-conotoxin peptide CnIIIC mutant and the use thereof. Further provided are a nucleic acid construct of the μ-conotoxin peptide CnIIIC mutant, and an expression vector and transformed cell thereof, and the use thereof. The μ-conotoxin peptide CnIIIC mutant has an enhanced transdermal penetration ability, and can effectively penetrate the skin barrier to directly act on nerves and muscle tissues in the underlying layer of skin. By means of the unique physical and chemical properties, the mutant can realize a local pharmaceutical effect within a relatively short period of time, thereby greatly improving the bioavailability of a drug.

The present application relates to a kind of skin care composition for improving female menopausal aging and its application, the skin care composition for improving female menopausal aging includes the following components: conotoxin peptide, bakuchiol, alfalfa extract and radix pseudostellariae extract, the weight ratio of conotoxin peptide, bakuchiol, alfalfa extract and radix pseudostellariae extract is (0.1-5) :(0.1-3) :(0.1-5) :(0.1-3). The four are by means of inhibiting neurotransmitter, regulating hormone etc., enhance skin health, effectively improve the problem of menopausal female skin aging, make skin firm and smooth.

The present invention provides a conotoxin KIIIA mutant with an amino acid sequence of SEQ ID NO: 1: Xaa1CXaa2CSXaa3KWCXaa4DHXaa5RXaa6C*, where "*" represents C-terminal amidation. The present invention also provides a preparation method and applications thereof. The present invention not only retains the activity, conformation and stability of the wild polypeptide, but is also easier to synthesize compared to the wild polypeptide.

The invention belongs to the technical field of biological medicines, and relates to a mutants of mu-conotoxin KIIIA rich in positive charges and application of the mutants. The mutant is obtained by carrying out site-directed mutagenesis on C1A, K7R and C15R on a natural mu-conotoxin KIIIA sequence; the amino acid sequence of the mutant is shown as SEQ ID NO. 1 in a sequence table. According to the invention, a series of mutants which are simple and convenient to synthesize and have a remarkable inhibition effect on a NaV1.4 channel are obtained by performing systematic structural optimization on a parent peptide KIIIA containing three pairs of disulfide bonds and adopting a strategy of combining disulfide bond deletion and amino acid site-directed mutagenesis. Furthermore, non-natural amino acid Pen is introduced into the mutant with the optimal activity, so that the stability of the mutant in vivo is remarkably enhanced, and the action time is prolonged.

The invention provides a method for rapidly preparing recombinant conopeptide through one-step chromatography and application. According to the method disclosed by the invention, after fermentation liquor of conopeptide subjected to recombinant expression of a pichia pastoris system is subjected to crude purification, the refined purification of the conopeptide subjected to enzyme digestion is completed only through a one-step cation chromatography method, and the high-purity conopeptide with the purity of 98% or above is obtained. The invention further finds that the conopeptide biosynthesized by using a pichia pastoris expression system has the characteristics of high yield and easiness in large-scale production, the TrxA tag protein is screened and adopted, so that folding and expression of the recombinant conopeptide are efficiently promoted, and the TrxA tag protein has oxidation-reduction activity, so that a suitable environment is provided for formation of disulfide bonds of the conopeptide, and the conopeptide has a good application prospect. The problem of disulfide bond mismatching is obviously reduced. The invention provides an effective solution for biosynthesis and large-scale production of conopeptide.

The invention belongs to the technical field of biological medicines, and relates to a superoxide dismutase / mu-conotoxin sustained-release compound based on a galactomannan covalent shell and application of the superoxide dismutase / mu-conotoxin sustained-release compound. Galactomannan in the compound is oxidized by NaIO4 and is coupled with stearic acid to form a stearic acid-oxidized galactomannan shell-core structure, mu-conotoxin is connected with galactomannan through a covalent bond, superoxide dismutase is loaded into the shell-core structure, and the structural formula of the compound is as follows: SA-O-CM-mu-CnIIICn / SODm. Wherein n is a natural number from 3 to 11, and m is a natural number from 1 to 8. The SOD and the mu-CnIII C are loaded into the galactomannan covalent shell layer, so that the stability and the biological activity of the SOD and the mu-CnIII C can be effectively improved, degradation of hydrolase on protein and polypeptide is resisted, and the compound is endowed with excellent antioxidant, anti-wrinkle, anti-inflammatory and anti-radiation activity.

The invention belongs to the fields of biological medicine and neuroscience, and relates to an analogue of alpha O-conotoxin polypeptide GeXIVA, and a pharmaceutical composition and application thereof. Specifically, the invention relates to a separated polypeptide which comprises 2, 3, 4, 5, 6, 7 or 8 mutations on the basis of a mother sequence as shown in SEQ ID NO: 1, and comprises the following mutation: V28D or V28K. The polypeptide can specifically block alpha9alpha10nAChR, and has a good application prospect in preparation of analgesic drugs, drugs for treating nervous system diseases or cancers or neuroscience tool drugs and the like.

The invention discloses a mu-type conotoxin peptide, polynucleotide encoded by the mu-type conotoxin peptide and application of the mu-type conotoxin peptide. The amino acid sequence of the mu-type conotoxin peptide is shown as SEQ ID NO. 1. The invention provides a mu-type conotoxin peptide with higher biological activity than wild-type mu-type conotoxin, which can specifically block a Nav1.4 channel and reduce muscle contraction so as to be helpful for preventing and reducing wrinkles, and also can provide local anesthesia and reduce muscle activity, thereby playing an important role in the fields of beauty and medical treatment.

The application relates to the technical field of eye care products, and particularly discloses an eye essence cream and a preparation method thereof. The eye essence cream comprises a moisturizing agent, an antioxidant, a penetration promoter, a viscosity regulator, an emulsifier, an emollient, a thickening agent, Coffea arabica seed oil, Baphia nitida bark extract, an anti-wrinkle composition, a Mei flower extract, a Pediococcus / Parsnip root ferment filtrate, an Adzuki bean seed extract, caprylyl glycol, acetyl hexapeptide-8, acetyl tetrapeptide-2, lactose, whey protein, lactic acid and the like. The anti-wrinkle composition is prepared by mixing acetyl hexapeptide-8, conotoxin, Hedychium spicatum extract, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The eye essence cream provided by the application has a comprehensive and efficient improvement effect on complex problems such as dry skin, fine lines, relaxation, dark circles and eye bags.

This invention discloses μ-type conotoxin peptide [Ser 17 ]-dR-μ-CnIIIC and its applications. The μ-type conotoxin peptide [Ser] provided by this invention 17 ]-dR-μ-CnIIIC, whose amino acid sequence is shown in SEQ ID NO.1. μ-type conotoxin peptide [Ser 17 Compared to wild-type μ-CnIIIC, dR-μ-CnIIIC exhibits 20-fold increased animal activity, with its IC50... 50 It contains 10 times more conotin than wild-type conotin. Furthermore, [Ser...] 17 The amino acid sequence of ]-dR-μ-CnIIIC is reduced by one position compared to wild-type μ-CnIIIC, which can further reduce the synthesis cost. The [Ser] of this invention... 17 ]-dR-μ-CnIIIC expands the application of μ-type conotoxin peptides in the biomedical field.

This invention belongs to the field of biomedicine and relates to a novel α-conotoxin peptide LvIE and LvIF, its pharmaceutical composition, and its uses. An isolated polypeptide has an amino acid sequence as shown in any one of SEQ ID NOs:4-5 and SEQ ID NOs:7-8. The α-conotoxin peptide of this invention can effectively and specifically block α3β2 acetylcholine receptors and α6β2*nAChRs acetylcholine receptors, and has the potential to prevent and treat neuralgia, addiction, Parkinson's disease, dementia, schizophrenia, or depression, showing promising application prospects.

The invention discloses a preparation method and application of a terpene alcohol body of permeation-enhancing conopeptide, and belongs to the technical field of cosmetics. The terpene alcohol body for enhancing the permeation of conopeptide provided by the invention comprises the following components in percentage by mass: 1 to 15 percent of phospholipid, 0.1 to 10 percent of lysophosphatidylcholine, 0.5 to 3 percent of cholesterol, 0.01 to 2 percent of terpene, 2 to 50 percent of polyhydric alcohol, 0.001 to 1 percent of conopeptide and the balance of deionized water. On the basis of molecular docking, phospholipid and lysophosphatidylcholine with specific types and proportions are screened and used for entrapment of conopeptide, and terpene alcohol with stable structure and conopeptide entrapment efficiency greater than 90% is obtained; according to the preparation method, a terpenol body is added, a lysophosphatidylcholine, terpene and polyhydric alcohol ternary permeation enhancing system is uniformly integrated to the terpenol body, finally, the transdermal capacity of conopeptide is remarkably enhanced, the transdermal depth of conopeptide is promoted, the intradermal cumulant of conopeptide is increased, and a foundation is laid for achieving the effect of the conopeptide in cosmetics.

The invention relates to the technical field of masks, and discloses a conopeptide and ergothioneine combined antioxidant glowing mask process which comprises the following components in percentage by mass: an active component composition: 0.01-0.1% of liposome coated conopeptide and 0.2-1.0% of liposome coated ergothioneine; the matrix components comprise 50-70% of water, 3-8% of glycerol, 2-5% of butanediol, 2-5% of nicotinamide, 1-5% of squalane and 3-8% of meadowfoam seed oil; the emulsifying agent is prepared from the following components in percentage by weight: 0.5 to 2 percent of polyglycerol-10 laurate, 0.5 to 1.5 percent of sorbitol polyether-30 tetraoleate and 0.1 to 0.5 percent of sodium polyacryloyldimethyl taurate. According to the invention, the direct contact between the active peptide and the antioxidant is blocked through the combination of double-cabin isolated packaging and a liposome freeze-drying technology, and chain degradation caused by mutual exclusion of components is thoroughly avoided through physical separation and glassy state curing.

The invention discloses analgesic active peptides CSK and CSC designed based on AI as well as a preparation method and application thereof, relates to the technical field of biological medicines and the field of biological active peptides, and in particular relates to the analgesic active peptides CSK and CSC designed based on AI as well as the preparation method and application thereof in preparation of analgesic drugs and cosmetics. The analgesic active peptide CSK or CSC can be mixed with a pharmaceutically acceptable carrier to prepare clinically acceptable injections and oral preparations for preparing analgesic drugs. The analgesic active peptides CSK and CSC provided by the invention have better analgesic activity, the preparation method has simple steps, and the yield is higher. The invention has important guiding significance and practical value for clinical transformation and industrialization of conotoxin.

The invention discloses a human XVII type collagen-conotoxin recombinant fusion protein as well as an expression method, an expression recombinant plasmid and a construction method thereof, and belongs to the technical field of gene engineering. The preparation method comprises the following steps: acquiring a human-derived XVII type collagen gene segment 17A, a mu type conotoxin gene segment and orthologous promoter segments from different methylotrophic yeast by virtue of PCR (Polymerase Chain Reaction) cloning, and connecting the human-derived XVII type collagen gene segment 17A, the mu type conotoxin gene segment and the orthologous promoter segments by virtue of a Gibson Assessment seamless connection technology, so as to construct an expression recombinant plasmid pPIC9K-FMD-mu-CnIIIC-17A; the expression recombinant plasmid can express a human-derived X VII type collagen-conotoxin recombinant fusion protein with excellent cell adhesion activity, cell migration promotion activity and biological activity of promoting tissue regeneration and hair follicle repair and regeneration in a pichia pastoris GS115 expression system. And the phenomena of difficult exocytosis and easy degradation of the current human X VII type collagen are overcome.

The invention belongs to the technical field of biological medicines, and relates to a spiro polypeptide with a single disulfide bond and a mutant and application thereof. The amino acid sequence of the conotoxin polypeptide is shown as SEQ ID NO.1 in a sequence table. One or more amino acid site-directed mutagenesis is carried out on the amino acid sequence of the conotoxin polypeptide to obtain a series of mutants. A plurality of mutants have better inhibitory activity and selectivity on an alpha9alpha10 acetylcholine receptor; wherein the IC50 of the M16R is 28.2 nM, and the IC50 of the F19R is 17.5 nM. In addition, M16R and F19R show in-vivo analgesic activity in a chemotherapeutic drug oxaliplatin induced rat crymodynia model, and have the potential of being developed into a neuropathic pain treatment drug targeting alpha9alpha10nAChR.

The invention relates to the technical field of cosmetics, and particularly discloses an anti-aging composition for reducing pressure type fatigue as well as a preparation method and application of the anti-aging composition. The anti-aging composition comprises a camellia nitidissima extract, a tephrosia sinensis seed extract, mu-conopeptide and ascorbic acid polypeptide, the mass ratio of the camellia nitidissima extract to the tephrosia sinensis seed extract to the mu-conopeptide to the ascorbic acid polypeptide is (0.1-5): (0.01-2): (0.001-1): (0.01-5). The anti-aging composition provided by the invention improves the problems of dull skin, rough skin, loose skin and fine wrinkles caused by staying up late, working and mood pressure by reducing skin cell pressure injury and improving cell viability, and is mild, non-irritant and suitable for people with sensitive skin to use.

The invention provides a preparation method of a [mu]-conotoxin disulfide bond substitute, which comprises the following steps: on the basis of Fmoc solid-phase synthesis and DADA module embedding technology, coupling amino acid residues under the assistance of automatic microwaves to prepare a linear precursor peptide of [mu]-conotoxin, and carrying out in-situ oxidation and thiolysis activation on the linear precursor peptide to obtain the [mu]-conotoxin disulfide bond substitute. And carrying out folding oxidation on the obtained cyclized peptide by using natural chemical connection to assist cyclization so as to form the mu-conotoxin disulfide bond substitute. According to the method, the three-dimensional conformation and biological activity of the natural peptide are kept, meanwhile, efficient and rapid synthesis of the large-span disulfide bond substituted bridging peptide is achieved, the structural stability of the peptide product is remarkably improved, the reaction condition is mild and easy to control, the process is simple, the separation yield of the target product is stable, and the method can be used for rapidly preparing various variants and has wide application prospects. Different production and research requirements are met, and good market application prospects are achieved.

The present invention provides a modified conotoxin polypeptide, a preparation method and an application thereof, belonging to the technical field of cosmetics preparation. On the basis of the wild-type μ-conotoxin polypeptide PIIIA, the present invention modifies amino acid residues, moderately weakens the blocking effect of the μ-conotoxin polypeptide on sodium channels, and at the same time takes into account maintaining stability under acidic and alkaline conditions, maintaining stable isoelectric point and target specificity. The modified conotoxin polypeptide provided by the present invention has the characteristics of stability and low production cost. After modification, the conotoxin polypeptide still maintains a strong anti-wrinkle function. By using the modified conotoxin polypeptide, it is possible to avoid facial muscle stiffness and paralysis caused by excessive inhibition of the skeletal muscle sodium channel Nav1.4. At the same time, the risk of inhibiting cardiac sodium channels and brain sodium channels is also significantly reduced, and it is easy to penetrate the membrane and be absorbed.

The invention provides a mu-conopeptide fusion protein and a preparation method of mu-conopeptide, and belongs to the technical field of biology. The invention provides a [mu]-conopeptide fusion protein. The [mu]-conopeptide fusion protein comprises a folded protein in a connected state and [mu]-conopeptide which is repeatedly connected in series, the folded protein comprises thioredoxin and disulfide bond isomerase; the amino acid sequence of the mu-conopeptide is as shown in SEQ ID NO: 1. According to the method disclosed by the invention, the thioredoxin and the disulfide bond isomerase are used as folding proteins, so that the tandem expressed mu-conopeptide can correctly and effectively form the mu-conopeptide with three pairs of disulfide bonds, and the method can effectively improve the yield of the mu-conopeptide. In addition, the [mu]-conopeptide fusion protein can be used for biosynthesizing [mu]-conopeptide, and compared with a traditional method, the [mu]-conopeptide fusion protein is more environmentally friendly, lower in cost compared with solid-phase synthesis and suitable for large-scale production.

The application belongs to the technical field of biological medicine, and relates to a mutant of mu-conotoxin KIIIA rich in positive charges and application thereof. The mutant is obtained by performing C1A, K7R and C15R site-directed mutation on a natural mu-conotoxin KIIIA sequence; and the amino acid sequence of the mutant is shown in the sequence table SEQ ID NO. 1. The application performs systematic structural optimization on a parent peptide KIIIA containing three pairs of disulfide bonds, adopts a strategy of combining disulfide bond deletion with site-directed amino acid mutation, and obtains a synthetic simple mu-conotoxin KIIIA mutant which has a significant inhibitory effect on Na V 1.4 A series of mutants with significant inhibitory effect on the channel. Further by introducing non-natural amino acid Pen in the most active mutant, the stability in vivo is significantly enhanced, thereby prolonging the action time.

The present invention belongs to the field of biomedicine technology, and specifically relates to an anti-thrombotic polypeptide Cb17037 and its application. The anti-thrombotic polypeptide Cb17037 provided by the present invention is screened from cone snail toxin, has no bleeding risk at a concentration of 20 mg / kg and below, and has a good improvement effect on carotid artery injury and ischemic stroke. The anti-thrombotic polypeptide Cb17037 of the present invention has a significant inhibitory effect on platelet activation and aggregation induced by PAR‑1 AP, but has no significant effect on basic coagulation indicators such as APTT, PT and TT. The anti-thrombotic polypeptide Cb17037 of the present invention has an anti-thrombotic effect in vivo and in vitro, can be used to prepare products that inhibit platelet activation and / or aggregation, anti-thrombotic drugs, prevent and / or treat thrombotic diseases, and has a lower risk of bleeding.

1. Name of the product in this design: Packaging Can (Conocospirone). 2. Purpose of this design: This design is used for product packaging. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key features: the front view.